Evidence map›Paper›PMID 29298674›Full record

ArticleBMC cancer2018

IMMUNEPOTENT CRP induces cell cycle arrest and caspase-independent regulated cell death in HeLa cells through reactive oxygen species production.

Ana Carolina Martínez-Torres, Alejandra Reyes-Ruiz, Milena Benítez-Londoño, Moises Armides Franco-Molina, Cristina Rodríguez-Padilla

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06676709 (Effect of IMMUNEPOTENT-CRP, a Bovine Dialyzable Leukocyte Extract, on Serum Pro-Inflammatory Cytokines in Outpatients with Mild to Moderate COVID-19), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06676709 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation

Effect of IMMUNEPOTENT-CRP, a Bovine Dialyzable Leukocyte Extract, on Serum Pro-Inflammatory Cytokines in Outpatients with Mild to Moderate COVID-19: a Randomized, Double-Blind, Placebo-Controlled Study

TypeinterventionalSponsorUniversidad Autonoma de Nuevo LeonRan2021 to 2022Enrolled80ConditionsCOVID-19, SARS-CoV2 InfectionArmsIMMUNEPOTENT-CRP (I-CRP), Placebo Comparator
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ana Carolina Martínez-TorresUniversidad Autónoma de Nuevo León, Facultad de Ciencias Biológicas, Laboratorio de Inmunología y Virología, 66455, Monterrey, Mexico. ana.martinezto@uanl.edu.mx.ORCID 0000-0002-6183-0089
Alejandra Reyes-RuizUniversidad Autónoma de Nuevo León, Facultad de Ciencias Biológicas, Laboratorio de Inmunología y Virología, 66455, Monterrey, Mexico.
Milena Benítez-LondoñoUniversidad Autónoma de Nuevo León, Facultad de Ciencias Biológicas, Laboratorio de Inmunología y Virología, 66455, Monterrey, Mexico.
Moises Armides Franco-MolinaUniversidad Autónoma de Nuevo León, Facultad de Ciencias Biológicas, Laboratorio de Inmunología y Virología, 66455, Monterrey, Mexico.
Cristina Rodríguez-PadillaUniversidad Autónoma de Nuevo León, Facultad de Ciencias Biológicas, Laboratorio de Inmunología y Virología, 66455, Monterrey, Mexico.
Universidad Autónoma de Nuevo León · MX

Funding

Proyecto de Apoyo a la Incorporación de Nuevos PTC DSA/103.5/14/10812
6 · The paper itself

Abstract

backgroundRegulated cell death (RCD) is a mechanism by which the cell activates its own machinery to self-destruct. RCD is important for the maintenance of tissue homeostasis and its deregulation is involved in diseases such as cervical cancer. IMMUNEPOTENT CRP (I-CRP) is a dialyzable bovine leukocyte extract that contains transfer factors and acts as an immunomodulator, and can be cytotoxic to cancer cell lines and reduce tumor burden in vivo. Although I-CRP has shown to improve or modulate immune response in inflammation, infectious diseases and cancer, its widespread use has been limited by the absence of conclusive data on the molecular mechanism of its action.

methodsIn this study we analyzed the mechanism by which I-CRP induces cytotoxicity in HeLa cells. We assessed cell viability, cell death, cell cycle, nuclear morphology and DNA integrity, caspase dependence and activity, mitochondrial membrane potential, and reactive oxygen species production.

resultsI-CRP diminishes cell viability in HeLa cells through a RCD pathway and induces cell cycle arrest in the G2/M phase. We show that the I-CRP induces caspase activation but cell death induction is independent of caspases, as observed by the use of a pan-caspase inhibitor, which blocked caspase activity but not cell death. Moreover, we show that I-CRP induces DNA alterations, loss of mitochondrial membrane potential, and production of reactive-oxygen species. Finally, pretreatment with N-acetyl-L-cysteine (NAC), a ROS scavenger, prevented both ROS generation and cell death induced by I-CRP.

conclusionsOur data indicate that I-CRP treatment induced cell cycle arrest in G2/M phase, mitochondrial damage, and ROS-mediated caspase-independent cell death in HeLa cells. This work opens the way to the elucidation of a more detailed cell death pathway that could potentially work in conjunction with caspase-dependent cell death induced by classical chemotherapies.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCaspasesCattleCell Cycle CheckpointsCell ExtractsC-Reactive ProteinFemaleHeLa CellsHumansMembrane Potential, MitochondrialMitochondriaReactive Oxygen SpeciesUterine Cervical NeoplasmsAntineoplastic AgentsCaspasesCell ExtractsC-Reactive ProteinReactive Oxygen SpeciesApoptosisbDLEBovine dyalisable leukocyte extractCell deathCervical cancerI-CRPImmunomodulatorImmunotherapyTransfer factor

Identifiers

PMID29298674
PMCPMC5753472
OpenAlexW2782408653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.